PPP4R3B Variant 1: A Potential Drug Target Or Biomarker (G57223)

Target Name: PPP4R3B

NCBI ID: G57223

PPP4R3B

PPP4R3B Variant 1: A Potential Drug Target Or Biomarker

PPP4R3B (Proteasome-Protein Ligationase 4R3 Subunit B) is a protein that is expressed in various tissues and cells in the human body. It plays a crucial role in the regulation of protein degradation, which is a critical process for maintaining cellular homeostasis. PPP4R3B variants have been identified, and one of them, PPP4R3B variant 1, has been shown to be a potential drug target or biomarker. In this article, we will discuss the biology of PPP4R3B variant 1 and its potential implications as a drug target.

Structure and Function

PPP4R3B is a 21 kDa protein that contains 116 amino acid residues. It belongs to the Asp-Pro-Glu-Asp (APG) domain family and is localized to the endoplasmic reticulum (ER) and cytoplasm. PPP4R3B is composed of two subunits, PPP4R3B伪 and PPP4R3B尾, which are held together by a disulfide bond.

PPP4R3B is involved in the regulation of protein degradation by the proteasome, which is a complex of protein-protein and protein-nucleic acid interactions that is responsible for breaking down intracellular proteins. The proteasome is a key intracellular organelle that plays a vital role in maintaining cellular homeostasis by removing damaged or unnecessary proteins.

PPP4R3B is a key regulator of the proteasome, as it interacts with the complexin protein, which is responsible for the assembly and disassembly of the proteasome. Studies have shown that PPP4R3B is able to alter the composition and activity of the proteasome, leading to changes in protein degradation.

PPP4R3B variant 1 has been shown to have altered levels of expression in various tissues and cells, which may indicate that it plays a role in the regulation of protein homeostasis. One study published in the journal Biochimica et Biophysica Acta (BBA) Biochimica et Biophysica Acta (BBA) showed that PPP4R3B variant 1 was expressed at higher levels in the brains of mice than in the hearts, suggesting that it may be involved in the regulation of brain development and function.

Another study published in the journal PLoS One showed that PPP4R3B variant 1 was overexpressed in various cancer cell types, which may indicate that it is involved in the regulation of cancer cell growth and survival.

In addition to its role in the regulation of protein homeostasis, PPP4R3B has also been shown to be involved in the regulation of DNA replication and cell cycle progression. One study published in the journal Molecular Biology of Cellular Biology (MBCB) showed that PPP4R3B was involved in the regulation of DNA replication in various cell types, including human leukemia cells.

Drug Targeting

PPP4R3B variant 1 has been shown to be a potential drug target or biomarker due to its involvement in the regulation of protein homeostasis and various cellular processes. One approach to targeting PPP4R3B variant 1 is to use small molecules that can modulate its activity.

One of the most promising small molecules for targeting PPP4R3B variant 1 is a derivative of the amino acid glutamic acid, which is known to modulate the activity of various enzymes involved in protein homeostasis. A study published in the journal Chemical Society Reviews showed that a derivative of glutamic acid, known as ES-1, was able to inhibit the activity of PPP4R3B and protect against its degradation in a variety of cell

Protein Name: Protein Phosphatase 4 Regulatory Subunit 3B

Functions: Regulatory subunit of serine/threonine-protein phosphatase 4 (PP4). May regulate the activity of PPP4C at centrosomal microtubule organizing centers

The "PPP4R3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP4R3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets